119 results about "Neovascularization" patented technology

Systems and methods for analyzing pathologies utilizing quantitative imaging are presented herein. Advantageously, the systems and methods of the present disclosure utilize a hierarchical analytics framework that identifies and quantify biological properties / analytes from imaging data and then identifies and characterizes one or more pathologies based on the quantified biological properties / analytes. This hierarchical approach of using imaging to examine underlying biology as an intermediary to assessing pathology provides many analytic and processing advantages over systems and methods that are configured to directly determine and characterize pathology from underlying imaging data.

Systems and methods for analyzing pathologies utilizing quantitative imaging are presented herein. Advantageously, the systems and methods of the present disclosure utilize a hierarchical analytics framework that identifies and quantify biological properties / analytes from imaging data and then identifies and characterizes one or more pathologies based on the quantified biological properties / analytes. This hierarchical approach of using imaging to examine underlying biology as an intermediary to assessing pathology provides many analytic and processing advantages over systems and methods that are configured to directly determine and characterize pathology from underlying imaging data.

The invention provides a whole-process targeting polypeptide, a drug compound thereof, a drug delivery system and application of the whole-process targeting polypeptide. The whole-process targeting polypeptide comprises pHA and VAP which are covalently connected through a bridging structure; the VAP is LVAP, a reverse sequence polypeptide of the LVAP, DVAP or SVAP; wherein the amino acid sequence of the LVAP is as shown in SEQ ID NO: 1; the SVAP is a D-configuration polypeptide of the LVAP; the DVAP is a D-configuration polypeptide of the LVAP inverted sequence polypeptide; the bridging structure is amino-monoethylene glycol-carboxylic acid or a derivative thereof. The whole-process targeting polypeptide not only can cross a blood-brain barrier, target tumor neovascularization, cross a blood-tumor barrier, target tumor mimicry vessels, tumor cells and stem cells thereof, but also has better tumor cell affinity, anti-tumor treatment and in-vivo safety effects. Meanwhile, the drug compound or the drug delivery system has a synergistic effect after being combined with a chemotherapeutic drug, and the anti-tumor drug effect can be remarkably improved.

The invention relates to morin nanoparticles, pH responsive hydrogel and application of the morin nanoparticles and the pH responsive hydrogel. The morin-loaded nanoparticles provided by the invention can be rapidly degraded in an alkaline environment, have certain stability in an acidic environment, have the capability of releasing morin in response to pH, and can realize accurate regulation and control of morin release according to the change of environmental pH. According to the invention, hyaluronic acid is further subjected to methacrylation treatment, such that MeHA is obtained. The characteristic that MeHA is easier to degrade in an acid environment is utilized, and MeHA is used as hydrogel to load CFMNPs and can be effectively used for treating wounds caused by burns and frostbite. Furthermore, the pH responsive double-layer hydrogel based on pigment nanoparticles-basic fibroblast growth factors can realize sequential release of the effective components according to the change of the pH value of the burn or frostbite wound. The composition can effectively inhibit inflammation, resist oxidative stress, promote proliferation and migration of endothelial cells, promote neovascularization and finally accelerate wound healing.

The invention discloses a VEGF / TIE-2 dual-targeting polypeptide and application thereof in preparation of antitumor drugs, and relates to the technical field of biological medicines. The VEGF / TIE-2 dual-targeting polypeptide (named as RTP) provided by the invention is formed by combining an amino acid sequence capable of identifying VEGF and TIE-2 in a targeting manner, an amino acid sequence capable of forming beta-sheet nanofibers through self-assembly, an amino acid sequence capable of identifying carbonic anhydrase IX in a targeting manner and an enzyme reactive amino acid sequence capable of realizing MMP-2 specific shearing. The RTP can be subjected to allosteric and self-assembly in tumor cells to form stable water-insoluble nanofibers, the formation and metastasis of tumor neovascularization are strongly inhibited through VEGF and TIE-2 double signal channels, and the tumor progress is inhibited.

The invention discloses hydrogel for repairing volumetric muscle defects and a preparation method of the hydrogel, and the hydrogel is prepared from oxidized dextran, an alcohol-polyamino acid-bilirubin polymer and 3, 3 '-dithio-bis (propionyl hydrazide) according to the weight ratio of (50-75): (4-20): 1. The alcohol-polyamino acid-bilirubin polymer is prepared from an alcohol-polyamino acid polymer and bilirubin in a weight ratio of (6-25): 1. The hydrogel prepared by the invention not only has good characteristics of pH / ROS responsiveness, relatively strong tissue adhesion, antibacterial property, oxidation resistance and relatively low cytotoxicity, but also can remarkably promote cell migration, proliferation, new angiogenesis and myoblast differentiation, promote recovery of muscle structures and motor functions after volumetric muscle defects, and improve the recovery rate of muscle tissues and motor functions after the volumetric muscle defects. The material is expected to become a novel bioactive material capable of promoting volume muscle defect repair, and has a good application prospect in clinical treatment of large-volume tissue defect regeneration.

The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs) for use in treating or reducing the risk of developing or preventing: (i) neovascularization and / or (ii) inflammatory disorder, in particular, ophthalmic disorders associated with neovascularization and / or inflammation.

Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.

The invention relates to an iRGD modified dual drug-loading liposome and an application of the iRGD modified dual drug-loading liposome in radiotherapy sensitization of targeted glioblastoma. The liposome is composed of HSPC, CHO-HP, DSPE-mPEG2000, and DSPE-PEG2000-MAL, and is loaded with Osimertinib (Osimertinib) and Bortezomib (Bortezomib) through a pH (Potential of Hydrogen) gradient method, and the preparation method of the liposome comprises the following steps: carrying out a reaction on the Osimertinib (Osimertinib) and the Bortezomib (Bortezomib) in the presence of a Osimertinib is used as an EGFR inhibitor, bortezomib is used as a proteasome inhibitor, and osimertinib and bortezomib synergistically enhance the radiotherapy sensitivity by weakening the DNA repair capability of tumor cells. The iRGD peptide on the surface of the liposome is combined with tumor cell specific receptors alpha v beta 3 and NRP1 in a targeting manner, so that the liposome is mediated to pass through tumor neovascularization and efficiently deliver drugs to tumor parts. Animal experiment results show that the enrichment of the liposome in tumor tissues is obviously higher than that of common liposome, and the drug release has good controllability. Compared with the prior art, the invention has obvious advantages in tumor targeting, drug delivery efficiency and radiotherapy sensitization effect, is suitable for combined treatment of radiotherapy drug-resistant glioblastoma, and has a wide clinical application prospect.

The invention discloses hydrogel for promoting healing of diabetic wounds through cooperation of ganoderan-ferulic acid nanoparticles and rhEGF and a preparation method of the hydrogel. Belongs to the field of biomedical materials, and particularly relates to hydrogel for promoting healing of diabetic wounds and a preparation method thereof. The problem that healing of diabetic wounds is difficult due to the fact that the wounds are in the inflammation period for a long time is solved. The preparation method comprises the following steps: firstly, connecting ferulic acid to ganoderan through a chemical bond, then preparing nanoparticles through an anti-solvent precipitation method, and loading the nanoparticles and growth factors into temperature-sensitive hydrogel to obtain the CPP (at) GFNPs (at) EGF hydrogel. The hydrogel disclosed by the invention is used for regulating polarization of M1 type macrophages to M2 type macrophages, relieving inflammatory response at wounds, inhibiting bacterial growth and promoting formation of new vessels so as to promote healing of diabetic wounds. The preparation process of the hydrogel is simple to operate and convenient to use, and the hydrogel has good research, development and utilization prospects.

An amino-combretastatin derivative, and in particular a compound represented by general formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of the pharmaceutically acceptable salt thereof, a solvate thereof or a solvate of the pharmaceutically acceptable salt thereof, and an isomer thereof are provided. In general formula (I),R1 is selected from a C1-C3 alkyl or a C1-C3 haloalkyl, and R2 and R3 are respectively and independently selected from a C1-C6 alkyl, a C1-C6 haloalkyl or a C1-C6 alcohol group. The present invention also relates to the use of such compounds in the preparation of drugs for the treatment of diseases caused by abnormal neovascularization, and tubulin aggregation inhibitors.

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

The invention belongs to the technical field of biological medicine and food, and particularly relates to application of a water-soluble tomato concentrate in preparation of a composition for promoting wound healing and tissue regeneration. The invention finds that the water-soluble tomato concentrate can promote aggregation of macrophages and neutrophils at a wound part, increase the occurrence rate of neovascularization at the wound part, promote cell proliferation and promote tissue regeneration. The water-soluble tomato concentrate can serve as a functional component to be applied to products for promoting wound healing and tissue regeneration, the effect of the water-soluble tomato concentrate is close to or equivalent to that of human recombinant epidermal growth factors and adenosine, and the water-soluble tomato concentrate is mild in stress reaction, high in safety and wide in application prospect.

The invention discloses an application of sulfonated saccharide hydrogel containing sulfonated saccharide and a hydrogel matrix material in prevention and / or treatment of myocardial infarction. Specifically, the invention provides application of sulfonated saccharide hydrogel containing sulfonated saccharide and a hydrogel matrix material, and the sulfonated saccharide hydrogel is used for preparing a pharmaceutical composition for preventing and / or treating myocardial infarction. Wherein the molecular weight of the sulfonated saccharide is 1000Da-300000Da, the sulfur content is 0.5-30%, and the hydrogel matrix material comprises an extracellular matrix material and a derivative thereof. The sulfonated saccharide hydrogel can effectively promote neovascularization and cardiac function recovery after myocardial infarction under the condition that exogenous cells or growth factors are not introduced, ventricular hypertrophy and fibrosis degree in the later stage of infarction are remarkably inhibited, and a new thought is provided for clinical myocardial infarction transformation treatment.

The present invention relates to a composition for preventing or treating diabetic retinopathy, comprising a peptide having an excellent effect of inhibiting the generation of neovascularization in the retina, the loss of perivascular cells, and the expansion of blood vessels. The present invention can be effectively used in the prevention or treatment of retinopathy by inhibiting increase in vascular permeability, inflammation, and the occurrence of neovascularization.

Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina / vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

The application discloses a VEGF / TIE-2 double-targeting polypeptide and application thereof in preparation of an antitumor drug, and relates to the technical field of biological medicine.The VEGF / TIE-2 double-targeting polypeptide (named as RTP) provided by the application is composed of an amino acid sequence capable of target-recognizing VEGF and TIE-2, an amino acid sequence capable of self-assembling to form a beta-sheet nanofiber, an amino acid sequence capable of target-recognizing carbonic anhydrase IX and an enzyme-reactive amino acid sequence capable of being specifically cut by MMP-2.RTP can occur conformational change and self-assemble in tumor cells to form stable water-insoluble nanofibers, and can strongly inhibit tumor neovascularization and metastasis through the VEGF and TIE-2 double-signal pathways and inhibit the progress of the tumor.

A method for evaluating an intestinal anastomosis stent is provided. By establishing an animal model of mechanical intestinal obstruction, an intestinal anastomosis stent implantation environment is simulated after intestinal tumor surgery in patients. It was observed that in the digestive tract anastomosis after intestinal severance under this intestinal obstruction animal model, the implantation of the anastomosis stent can promote wound healing at the intestinal anastomosis site, and the degree of abdominal adhesion is reduced during the healing process, and the intestinal bursting pressure strength is well restored; at the same time, according to the tissue section analysis of this site, it can be seen that its tissue healing process conforms to the physiological healing law and is better than the healing of the group without stent implantation. Moreover, from the expression of the degree of inflammation, the expression of new blood vessels, and the degree of fibrosis, it can be judged by comparing the stent implantation group and the group without stent implantation whether the stent to be tested has a significant advantage in promoting healing after intestinal anastomosis in this mechanical intestinal obstruction animal model. This provides an intuitive detection method for evaluating new materials for preparing intestinal anastomosis stents.

The application discloses a choroid neovascularization image segmentation method based on a hybrid convolutional network, first, collecting fundus OCT scan images and labeling, and forming a data set by using the labeled images; a deep space-time separation hybrid convolutional neural network fusing an attention mechanism is constructed, two-dimensional feature extraction is carried out by using two-dimensional convolution, then the two-dimensional feature extraction is extended to three-dimensional, and then three-dimensional attention deep space-time separation convolution is carried out, and the two-dimensional feature and the three-dimensional feature are aligned and fused; then the hybrid neural network model constructed is trained by using the data set; finally, the trained hybrid neural network model is used to segment choroid neovascularization from the fundus OCT scan images, and a segmentation result is obtained. Through the space-time attention mechanism, local features of the choroid neovascularization image are better extracted, and by using the deep space-time separation convolution, a dimension reduction operation is carried out on the input feature map, so that the calculation parameters can be effectively reduced, thereby reducing the network calculation amount, and the channel attention can be more effectively calculated.

The present invention belongs to the technical field of pharmaceutical preparations, and specifically relates to a method for preparing a nanocomposite carrying PDGF-BB mRNA, the preparation method comprising: 1) preparing LNP carrying PDGF-BB mRNA: quickly mixing a lipid phase containing 7C1 cationic liposomes with an aqueous phase containing PDGF-BB mRNA to obtain LNPmRNA; 2) preparing a PLGA gas core core by a double emulsion method; 3) mixing the PLGA gas core core in step 2) with the LNPmRNA in step 1), and standing to obtain a LNPmRNA@PLGA nanocomposite. The LNPmRNA@PLGA nanocomposite of the present invention has the advantages of protection, targeting, visibility and responsiveness. It is combined with in vitro focused ultrasound, which can not only realize the visual delivery of drugs, but also qualitatively and semi-quantitatively evaluate the neovascularization in advanced atherosclerotic plaques, and improve the cell transfection efficiency under the targeted microbubble destruction effect of in vitro focused ultrasound, accurately and efficiently overexpress the target protein, achieve the goal of drug treatment, and reduce systemic toxic side effects.

Polyesteramide (PEA) copolymers are disclosed, having structures that include repeating units that contain various monomer residues characterized herein and present in the repeating units at defined ranges of molar equivalents. These copolymers can possess a number of important advantages for providing longer performing glucose sensors and / or for simplifying their design. For example, in vivo modeling has confirmed that these polymers exhibit both decreased collagen deposition and increased neovascularization (angiogenesis). Additional testing has demonstrated favorable oxygen and glucose transport capabilities, as well as other relevant properties.

The invention discloses an antibacterial hydroxyapatite fiber-gelatin composite scaffold as well as a preparation method and application thereof, the composite scaffold has the structural characteristics of regular spherical macropores and communicating pores, and the interior of the composite scaffold is formed by mutually interwoven antibacterial hydroxyapatite fiber-gelatin composite fibers; the preparation method comprises the following steps: injecting antibacterial hydroxyapatite fiber / gelatin turbid liquid into a paraffin ball template under negative pressure, and carrying out thermal cooling phase separation and a paraffin ball template leaching technology. The composite scaffold integrates multiple functions of active antibiosis, osteogenic differentiation promotion, neovascularization and bone tissue ingrowth and the like, and has huge application potential in the field of promotion of rapid repair and regeneration of infectious bone defects.

The invention belongs to the technical field of biological medicines, and particularly relates to application of human umbilical cord mesenchymal stem cells combined with metformin in preparation of anti-DFU medicines. By constructing a diabetic foot ulcer rat model and combining in-vivo and in-vitro experiments and signal analysis, it is confirmed for the first time that hUC-MSCs and metformin have a synergistic effect in treating diabetic foot ulcer. Combined treatment is beneficial to diabetic foot ulcer wound closure, reepithelization, matrix remodeling and proliferation of blood vessels and inflammation related cells, regulation and control of vascular endothelial cells PI3K-AKT and downstream signal channels thereof can be promoted through paracrine, so that the inhibited survival, proliferation, migration and vascularization capacities of the vascular endothelial cells PI3K-AKT in a hyperglycemia environment are recovered, and the vascular endothelial cells PI3K-AKT and the downstream signal channels of the vascular endothelial cells PI3K-AKT are promoted. Further, the dynamic regulation of enhancement, maturation and weakening of new angiogenesis of the wound of the DFU rat is promoted, and the wound healing is accelerated. The invention provides theoretical basis and experimental support for developing a more effective treatment scheme.

Provided herein are novel reprogrammed smooth muscle cells (rSMCs) and methods of making and using the cells for the treatment of ischemia. The rSMCs are produced by culturing a fibroblast with an all-trans-retinoic acid (ATRA) under conditions that produce the rSMC from the fibroblast, wherein the fibroblasts are genetically modified to overexpress myocardin. The rSMCs offer advantages over currently available regenerative vascular therapies by promoting vascular perfusion in a recipient subject. In particular, the rSMCs can increase neovascularization of both small and large vessels.

The invention provides a process for preparing a Biochanin A (BCA)-loaded hydroxypropyl methyl cellulose (HPMC) hydrogel aimed at promoting wound healing in diabetic patients. The hydrogel is prepared by dispersing HPMC in distilled water, followed by dissolving BCA into the mixture with continuous stirring, then storing under refrigeration. The therapeutic potential of Biochanin A (BCA) in promoting wound healing, is evaluated in rats induced with diabetes. The results showed that the BCA-loaded hydrogel accelerates diabetic wound repair by boosting antioxidant defenses via upregulating Nrf2 and related enzymes, suppressing inflammatory markers such as IL-1β, IL-6, TNF-α, COX-2, and TLR4, and stimulating angiogenesis through increased expression of TGF-β1, VEGF-A, and PDGFR. It promotes faster wound contraction, re-epithelialization, collagen deposition, granulation tissue formation, and neovascularization, potentially reducing the risk of complications like limb amputation. The invention offers a promising therapeutic approach for treating chronic diabetic wounds with improved healing outcomes.

This invention provides a method for treating ocular indications involving abnormal neovascularization. [Solution] The present invention provides a method comprising the step of administering an effective amount of nintedanib or a pharmaceutically acceptable salt thereof in the form of a topical eye drop or implant to the eye of a subject.

The utility model relates to a kind of nanostructure of laser surface treatment aggregate, wherein the surface of the aggregate is titanium metal, and at least one microchannel with titanium dioxide (TiO2) after cooling is formed by laser melting and sputtering to form molten titanium, at least one microchannel includes: at least one micropore, at least one guide channel, and at least one nano-wall formed at least one nano-bulge layer and at least one nano-wall. The following bone healing and antibacterial index effects and purposes are achieved: A. accelerate bone healing related protein deposition, B. accelerate bone cell attachment, C. induce neovascularization, D. accelerate early calcification and bone mineralization, E. improve nutrient exchange, F. stabilize surface bone structure, and G. resist plaque formation.

The present invention belongs to the field of tumor immunotherapy, and relates to a humanized anti-VEGF antibody Fab fragment. The present invention discloses nucleic acid sequences (including heavy / light chain variable regions) encoding said antibody fragment, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The anti-VEGF antibody Fab fragments disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2, and also neutralize the proliferative effect of VEGF on HUVEC cells. Compared to the full-length antibody, antibodies in the form of Fab fragments have stronger penetrability and less toxic in terms of gastrointestinal perforation, hypertension and hemorrhage and do not stimulate the complement cascade reaction, thus reducing the risk of endophthalmitis and autoimmune inflammatory reactions. Thus it could be used in clinical treatment of ocular diseases characterized by choroidal neovascularization, including but not limited to age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, choroidal neovascularization (CNV).

A film for integrating with tissue and promoting at least one of endothelial cell adhesion, migration, proliferation, ingrowth, infiltration, angiogenesis, sprouting angiogenesis, neovascularization, and vascularization includes a plurality of fibers arranged in an overlapping configuration to form a porous, thin film with an average pore size of at least 0.01 μm2 and less than 60 μm2. The plurality of fibers has an average diameter of at least 10 nm and less than 1,000 nm. Each of the plurality of fibers have an aspect ratio of length to width of at least 10, and each of the plurality of fibers is a biocompatible material.